Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study formulated and characterized a dutasteride-loaded nanocrystalline suspension for long-acting parenteral delivery, finding that it provided sustained drug release in rats with a significant reduction in local inflammation over 28 days following intramuscular injection.

This study reported that a liquid-liquid extraction method using methyl tert-butyl ether and methylene chloride was most effective for extracting dutasteride and its internal standard from rat plasma.

This study found that a dutasteride-loaded liposomal system significantly increased skin permeability and drug deposition in mouse skin compared to other formulations, suggesting improved localized treatment potential for androgenetic alopecia.

This study developed and validated a sensitive and rapid method to simultaneously measure alfuzosin and dutasteride in human plasma, enabling high-throughput analysis for pharmacokinetic and bioequivalence studies.

This review examines recent advancements in analytical techniques used to quantify dutasteride, a medication for enlarged prostate, in various biological samples and its commercial forms, emphasizing methods such as HPTLC, GC-MS, and HPLC.

New, cheaper method measures finasteride in tablets accurately and quickly.

This study found that the Mark Cuban Cost Plus Drug Company offers significant cost savings on men's health medications compared to both Medicare and GoodRx, particularly for erectile dysfunction treatments.

In this study, dutasteride treatment in retinitis pigmentosa mice increased photoreceptor survival and reduced glial activation, suggesting it may offer a neuroprotective effect.

This study found that a novel topical dutasteride lotion, FOL100, demonstrated excellent safety, tolerability, and usability with promising signs of clinical benefit for mild-to-moderate male pattern baldness.

This abstract discusses the FitSpresso weight loss supplement's potential benefits and mechanisms but provides no clinical research findings; it reports on its ingredients and consumer ratings instead.

This abstract highlights that preliminary results from the REDUCE trial indicate dutasteride may lower prostate cancer incidence by 23% in older men compared to a placebo.

This study found that the Mark Cuban Cost Plus Drug Company model offers substantial cost savings on men's health medications compared to Medicare and GoodRx, particularly for long-term treatments.

Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

This study found that non-daily use of Dutasteride may be more cost-effective and associated with lower cancer incidence than daily use for patients seeking treatment for lower urinary tract symptoms.

In this study of BPH patients with testosterone deficiency, the combination of TU and dutasteride reduced prostate volume and improved testosterone-related symptoms but was less effective for sexual function compared to TU alone, indicating caution in using dutasteride for those with sexual dysfunction concerns.

This review describes how dutasteride, a dual 5alpha-reductase inhibitor, has improved outcomes in benign prostatic hyperplasia and is being studied for prostate cancer prevention, without new data reported.

In this report, a participant in a Portuguese pharmacy master's program detailed their six-month internship at Farmácia Queija Ferreira, highlighting their involvement in medication preparation, creating educational resources, and studying drug interactions, including serious cases involving diclofenac and brimonidine.

This study emphasizes the need for a formal evaluation of direct-to-consumer telemedicine services in Australia to ensure safety, privacy, and ethical standards while maintaining high-quality healthcare.

This study found that a lipid-based nanoparticle formulation with oleic acid for delivering dutasteride showed lower skin permeation compared to a formulation without oleic acid, indicating its potential for targeted dermal delivery.

This study developed a topical dutasteride-loaded Insitu-emulgel for treating androgenetic alopecia, finding it effectively controls drug release, enhances skin penetration, and may improve patient compliance compared to traditional topical treatments, though further clinical research is underway.

This study developed three spectrophotometric methods to effectively measure finasteride in bulk and tablet forms, providing accurate results that align closely with labeled claims.

This study in identical twin males with androgenetic alopecia found that dutasteride significantly improved hair growth compared to placebo over one year.

This study found that a transdermal delivery system using 3% azone and P407 gel may enhance the skin permeation of doxazosin and finasteride for treating benign prostatic hyperplasia.

In this study, researchers optimized fast-dissolving tablets of nifedipine using a systematic approach, resulting in formulations that demonstrated rapid disintegration, enhanced dissolution profiles, and improved solubility, potentially improving oral delivery for patients requiring poorly soluble antihypertensive medication.

This study concluded that dutasteride modestly reduces nocturia in men but does not improve sleep quality.

This study found that using spanlastics, a nano, surfactant-based drug delivery system, improved the bioavailability, drug release characteristics, and pharmacokinetic behavior of famotidine, a poorly soluble drug, by enhancing its dissolution and membrane permeation.

Finasteride and dutasteride's effects are mainly due to target binding saturation and slow enzyme turnover.